FDA Raises Concerns Over Nonprescription Birth Control Pill

(Bloomberg) — Perrigo Co.’s birth-control product Opill faces a critical hurdle next week after US regulators raised concerns about whether it would be suitable as an over-the-counter drug. 

Opill may not be effective as an nonprescription pill given Americans’ increasing body weight, regulators said in briefing documents for an upcoming meeting. Staff also cited major limitations in crucial data submitted by the company in support of an over-the counter switch. 

US Food and Drug Administration posted the documents Friday in preparation for a meeting next week when agency advisers will vote on whether to recommend Opill’s over-the-counter sale, which would remove a substantial barrier to access.

While Opill has been available in the US with a prescription since 1973, reproductive rights advocates have long argued that oral contraception should be available over the counter, as it is in more than 100 countries.

HRA Pharma, Perrigo’s unit that makes the drug, sought FDA approval for an over-the-counter version last summer after the Supreme Court overturned the landmark Roe v. Wade ruling legalizing abortion nationally.

Shares of Perrigo fell 2% in New York.

More stories like this are available on bloomberg.com

©2023 Bloomberg L. P.